校对 穆祥桐 新京报讯（记者张秀兰）国家药监局近日发布公告，因存在实际生产工艺与注册申报的生产工艺不一致 等 问 题 ， 暂 停 进 口 VITAL LABORATORIES PVT. LTD. 生 产 的 地 高 辛 原 料 药 （ 登 记 号 ： Y20170000041）。 国家药监局近期组织对VITAL LABORATORIES PVT. LTD.（生产地址：Plot No.1710 & A1/2208, GIDC, Estate, 3rd Phase, VAPI-396 195. Gujarat, India.）开展现场检查，发现该工厂生产的地高辛原料药存在实 际生产工艺与注册申报的生产工艺不一致、生产工艺和关键参数变更研究不充分、未按照进口注册质量 标准检验放行、质量管理和质量保证系统不完善等情形，不符合我国《药品生产质量管理规范（2010年 修订）》和药品关联审评审批有关要求。 根据《中华人民共和国药品管理法》等有关规定，国家药监局决定，暂停进口上述原料药，各口岸药品 监督管理部门暂停发放该原料药产品的进口通关单；上述原料药在国家药监局药品审评中心"原辅包登 记信息"中"与制剂共同审评审批结果" ...

Core Viewpoint - The article discusses the impact of the recent drastic price cuts in the pharmaceutical industry, particularly focusing on the implications of the tenth batch of centralized procurement and the challenges faced by companies involved in the production of generic drugs [1][2]. Group 1: Centralized Procurement and Price Cuts - The tenth batch of centralized procurement has led to unprecedented price cuts, with some drugs like the injection of isopropyl phenol being bid at extremely low prices, raising concerns about quality and sustainability [2][4]. - The price of isopropyl phenol injection was bid at 0.22 yuan per unit, a 92.36% drop from the highest effective bid of 2.8805 yuan, highlighting the aggressive competition among 36 companies [4][5]. - The involvement of B-class pharmaceutical companies, which often outsource production and have minimal investment in R&D, has increased significantly, leading to a more competitive and potentially unstable market environment [10][11]. Group 2: Regulatory Challenges and Company Responses - Two companies, Haimeizhisun and Sichuan Taiji, faced penalties for failing to meet quality standards, resulting in an 18-month suspension from national procurement, indicating the regulatory scrutiny in the industry [2][3][4]. - The rapid increase in B-class companies, from 140 in January 2021 to 1172 by November 2023, reflects a shift in the industry where many companies prioritize low-cost production over quality assurance [10][11]. - The article notes that many B-class companies lack adequate quality management, leading to potential risks in drug production and compliance with regulatory standards [11][12]. Group 3: Market Dynamics and Competitive Pressures - The intense competition has forced companies to shorten drug development cycles, with some projects being completed in as little as 12 months, raising concerns about the thoroughness of research and development [18][19]. - Companies are increasingly focusing on cost control, with a shift towards using domestic raw materials to reduce expenses, reflecting the pressure to maintain profitability amid price cuts [21][22]. - The article highlights a trend where companies are reducing R&D budgets and personnel, leading to a decline in innovation and a potential long-term impact on the industry [22][23].